IBOGF (Universal Ibogaine) Current Accrued Expense: $0.42 Mil (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine Current Accrued Expense?

Universal Ibogaine IBOGF -13.85% Current Accrued Expense is $0.42 Mil as of Apr. 2025.

Universal Ibogaine's Current Accrued Expense for the quarter that ended in Apr. 2025 was $0.42 Mil.

Universal Ibogaine's quarterly Current Accrued Expense increased from Oct. 2024 ($0.33 Mil) to Jan. 2025 ($0.33 Mil) and increased from Jan. 2025 ($0.33 Mil) to Apr. 2025 ($0.42 Mil).

Universal Ibogaine's annual Current Accrued Expense increased from Jul. 2022 ($0.22 Mil) to Jul. 2023 ($0.37 Mil) but then declined from Jul. 2023 ($0.37 Mil) to Jul. 2024 ($0.33 Mil).

Universal Ibogaine Current Accrued Expense Related Terms

Universal Ibogaine Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Current Accrued Expense Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Current Accrued Expense
Get a 7-Day Free Trial 0.02 0.06 0.22 0.37 0.33

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.33 0.33 0.33 0.42

Universal Ibogaine Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.42 Mil mean?
Universal Ibogaine (IBOGF) has a Current Accrued Expense of $0.42 Mil as of Apr. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Current Accrued Expense too high?
Universal Ibogaine's current Current Accrued Expense is $0.42 Mil.
How does Universal Ibogaine's Current Accrued Expense compare to LABT and CALC?
Universal Ibogaine's Current Accrued Expense of $0.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Universal Ibogaine and its competitors. Universal Ibogaine's current Current Accrued Expense is $0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Current Accrued Expense of $0.42 Mil. The current Current Accrued Expense is $0.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Current Accrued Expense is $0.42 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.